Griss Johannes, Ratzinger Gudrun, Maul Julia-Tatjana, Weger Wolfgang, Thaçi Diamant, Carrascosa José Manuel, Jonak Constanze
Department of Dermatology Medical University of Vienna Vienna Austria.
Department of Dermatology Medical University of Innsbruck Innsbruck Austria.
Skin Health Dis. 2023 Jun 28;3(5):e263. doi: 10.1002/ski2.263. eCollection 2023 Oct.
In the literature there is no consensus on the correlation between early systemic intervention and better treatment response in psoriasis. Here we present data on the impact of disease duration (<5 years, 5-<10 years, and ≥10 years) on response to tildrakizumab treatment among patients with moderate-to-severe plaque psoriasis from the reSURFACE 1 and reSURFACE 2 phase 3 trials and the TRIBUTE phase 4 study. Overall, there was no significant effect of disease duration on the Psoriasis Area and Severity Index ≤1, ≤3, and ≤5, or the Dermatology Life Quality Index 0-1 response rates. Tildrakizumab was highly effective regardless of the psoriasis disease duration.
在文献中，对于银屑病早期全身干预与更好的治疗反应之间的相关性尚无共识。在此，我们展示了来自reSURFACE 1和reSURFACE 2 3期试验以及TRIBUTE 4期研究的中重度斑块状银屑病患者疾病持续时间（<5年、5 - <10年和≥10年）对替拉珠单抗治疗反应影响的数据。总体而言，疾病持续时间对银屑病面积和严重程度指数≤1、≤3和≤5，或皮肤病生活质量指数0 - 1的反应率没有显著影响。无论银屑病疾病持续时间如何，替拉珠单抗均具有高效性。
